ONO-8539

01/01/2014 - "The results of this study, which to our knowledge represents the first evaluation of ONO-8539 in patients with overactive bladder, suggest a minimal role for EP1 receptor antagonism in the management of overactive bladder syndrome."
01/01/2014 - "Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome."
01/01/2014 - "We evaluated the efficacy, safety and tolerability of the EP1 receptor antagonist ONO-8539 in patients with overactive bladder syndrome. "

10/01/2017 - "ONO-8539 is a potential novel therapeutic option for controlling heartburn symptoms in GERD patients. "
10/01/2017 - "In the present study, we focused on the PGE2 receptor, EP1, and investigated the effects of ONO-8539, a novel EP1 receptor antagonist, on heartburn symptoms in healthy male volunteers. "
10/01/2017 - "ONO-8539 attenuated acid-induced heartburn in healthy male subjects, suggesting that EP1 receptors play a role in generation of heartburn symptoms. "
10/01/2017 - "ONO-8539 significantly reduced a total heartburn symptom score, not other upper GI symptom scores, during acid perfusion compared with placebo (AUC for heartburn, 85.0 ± 10.6 for placebo and 56.5 ± 7.2 for ONO-8539; P < 0.01), and significantly extended the time to first sensation of heartburn compared with placebo (5.7 ± 4.3 min for placebo and 9.7 ± 7.2 min for ONO-8539; P < 0.05). "
10/01/2017 - "A novel prostanoid EP1 receptor antagonist, ONO-8539, reduces acid-induced heartburn symptoms in healthy male volunteers: a randomized clinical trial."

01/01/2014 - "Similar to other treatments, the most frequently reported adverse events after ONO-8539 were nasopharyngitis and diarrhea. "

10/01/2017 - "ONO-8539 is a potential novel therapeutic option for controlling heartburn symptoms in GERD patients. "

01/01/2014 - "Similar to other treatments, the most frequently reported adverse events after ONO-8539 were nasopharyngitis and diarrhea. "